Reference is made to the stock exchange announcement published by Lifecare ASA
(the "Company") on 8 October 2024, regarding the commencement of the
application period in the public retail offering (the "Offering") of up to
1,000,000 new shares (the "Offer Shares").

Hannibal Invest AS, a company closely associated with Hans Hekland, board
member of the Company, has today applied for 5,000 shares in the Offering at
an offer price of NOK 20 per Offer Share, subject to allocation by the Board
of Directors upon expiry of the application period for the Offering. Please
see the attached PDMR-form for further details.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO,  joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities
Trading Act, ยง5-12. The information was submitted for publication at
2024-10-10 15:10 CEST.